Subscribe
shutterstock_613544495-atmosphere1
Atmosphere1 / Shutterstock.com
25 June 2019Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute

A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Fed Circuit sides with Gilead over hep C patent
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.
Americas
Merck boosts oncology pipeline with $1bn deal
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.


Editor's picks

UKIPO rejects Boehringer’s SPC for horse inhaler
Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025

Editor's picks

Europe
UKIPO rejects Boehringer’s SPC for horse inhaler
8 July 2025
Americas
Bankruptcy judge approves $305m sale of genetics testing company
1 July 2025
Americas
A step too far? Why Stewart’s approach is dividing opinion
24 June 2025
Europe
Diverging in the detail: UPC local divisions and Court of Appeal take different paths
19 June 2025
Europe
UPC confirms permanent injunction against Curio in 10x tech dispute
17 June 2025
Americas
LSPN: In-house ‘chess game’ is the same, but the rules have changed
9 May 2025

More on this story

Big Pharma
Fed Circuit sides with Gilead over hep C patent
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.
Americas
Merck boosts oncology pipeline with $1bn deal
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.

More on this story

Big Pharma
Fed Circuit sides with Gilead over hep C patent
31 October 2019   The US Court of Appeals for the Federal Circuit has delivered a blow for Merck in a patent infringement dispute against Gilead, upholding one of its patents as invalid.
Americas
Merck boosts oncology pipeline with $1bn deal
22 May 2019   Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.

More features

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’
Powell Gilbert launches Düsseldorf office with leading patent litigator
Startups toolkit: Why investors want more than patents
J&J fends off generic schizophrenia drug bids
Kilpatrick adds ‘seasoned litigator’ as trademark partner
WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond
Startup challenges rival over brain monitoring tech at ITC
UKIPO rejects Boehringer’s SPC for horse inhaler